
Opinion|Videos|July 29, 2024
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Advertisement
Video content above is prompted by the following question(s):
- How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Major Bleeding Prevention, Treatment Requires Vigilance in Patients With ET
2
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
3
Medicare Insulin Savings Model Cuts Costs, Boosts Access, Report Finds
4
Executive Order on Homelessness Includes Several Policy Shifts: Katherine Koh, MD, MSc
5